Article
SASH3 is an unfavorable prognostic immune biomarker in patients with acute myeloid leukemia(AML).
2023-03-21
Abstract excerpt
<title>Abstract</title> <p>Background: Acute myeloid leukemia(AML) is a malignant clonal disease. As the most common type of leukaemia, it is characterised by poor treatment outcomes and a poor prognosis in both the paediatric and adult populations. Improving anti-tumour responses through immunomodulators is a promising strategy or a new avenue for AML treatment. <h4>Methods:</h4> Using publicly available data f...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 8ff483db-f00e-5a03-aede-585a621e93f8
- DOI
- 10.21203/rs.3.rs-2664195/v1
